SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-016027
Filing Date
2019-03-19
Accepted
2019-03-19 16:56:17
Documents
3
Period of Report
2019-03-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a19-6626_18k.htm 8-K 31886
2 EX-10.1 a19-6626_1ex10d1.htm EX-10.1 210839
3 EX-10.2 a19-6626_1ex10d2.htm EX-10.2 69471
  Complete submission text file 0001104659-19-016027.txt   313646
Mailing Address 399 THORNALL STREET FIRST FLOOR EDISON NJ 08837
Business Address 399 THORNALL STREET FIRST FLOOR EDISON NJ 08837 732-902-4000
ContraVir Pharmaceuticals, Inc. (Filer) CIK: 0001583771 (see all company filings)

IRS No.: 462783806 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36856 | Film No.: 19692059
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences